Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbCellera Biologics Inc.ABCL · Entity 4118 | Chief Financial Officer | August 14, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbCellera Biologics Inc.
Report date August 14, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 482,800 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Purchase · Acquired 37,200 · Balance 482,800 |
| Common SharesSEC Table I · non-derivative | IndirectBy spouse | 130,959 |
Reported balance
Holding disclosure · report date 2026-08-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 130,959 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 14, 2026 16:04 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 37,200 | $10.32 | $383,904.00 |
DisclosureSEC source: 0001834411-26-000008 · wk-form4_1786723463.xml · nonDerivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482,800 Read SEC document |
| June 03, 2026 Filed Jun 3, 2026 18:23 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionShare option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001834411-26-000006 · wk-form4_1780510993.xml · derivative · entry 3 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,501,849 Underlying: Common Shares · 250,000 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 03, 2026 Filed Jun 3, 2026 18:23 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionCommon Shares | 250,000 | $0.19 | $47,500.00 |
DisclosureSEC source: 0001834411-26-000006 · wk-form4_1780510993.xml · nonDerivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 445,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 19:48 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 42,600 | $3.42 | $145,692.00 |
DisclosureSEC source: 0001834411-26-000004 · wk-form4_1772221711.xml · nonDerivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,600 Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 17:11 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 808,898 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001834411-26-000002 · wk-form4_1767633111.xml · derivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,751,849 Underlying: Common Shares · 808,898 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 20:37 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 1,352,054 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001628280-25-000233 · wk-form4_1735936673.xml · derivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,942,951 Underlying: Common Shares · 1,352,054 shares Expires 2035-01-01 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 14, 2024 Filed Jan 16, 2024 23:18 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 770,416 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0001703057-24-000004 · wk-form4_1705447127.xml · derivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,590,897 Underlying: Common Shares · 770,416 shares Expires 2034-01-14 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 14, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| May 26, 2023 Filed May 26, 2023 18:53 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 14,500 | $6.85 | $99,325.00 |
DisclosureSEC source: 0001209191-23-032484 · doc4.xml · nonDerivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,000 Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 19:31 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionShare option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001209191-22-062412 · doc4.xml · derivative · entry 4 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,820,481 Underlying: Common shares · 50,000 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 19:31 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GiftCommon shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-062412 · doc4.xml · nonDerivative · entry 2 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,500 F1 · shares: This transaction represents a charitable donation of 50,000 common shares the reporting person donated on December 20, 2022. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 19:31 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionCommon Shares | 50,000 | $0.19 | $9,500.00 |
DisclosureSEC source: 0001209191-22-062412 · doc4.xml · nonDerivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 17:19 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare Options (right to buy) · Derivative | 485,661 | $0.00 Strike: $13.18 | $0.00 |
DisclosureSEC source: 0001209191-22-059568 · doc4.xml · derivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,870,481 Underlying: Common Shares · 485,661 shares Expires 2032-12-01 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| May 12, 2022 Filed May 16, 2022 18:13 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 85,000 | $5.79 | $492,150.00 |
DisclosureSEC source: 0001209191-22-029091 · doc4.xml · nonDerivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,500 Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 22:00 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionShare Options (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0001209191-21-069084 · doc4.xml · derivative · entry 3 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,384,820 Underlying: Common Shares · 500,000 shares Expires 2029-08-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 22:00 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionCommon Shares | 500,000 | $0.32 | $160,000.00 |
DisclosureSEC source: 0001209191-21-069084 · doc4.xml · nonDerivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 553,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2021 Filed Feb 3, 2022 23:54 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GiftCommon Shares | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006960 · doc5.xml · nonDerivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,500 F1 · shares: This transaction represents a charitable donation of 500,000 common shares the reporting person donated on December 10, 2021. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 22:58 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare Option (right to buy) · Derivative | 406,020 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-21-068849 · doc4.xml · derivative · entry 3 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,884,820 Underlying: Common Shares · 406,020 shares Expires 2031-12-07 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 7, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 11:05 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 14,000 | $14.61 | $204,540.00 |
DisclosureSEC source: 0001209191-21-064378 · doc4.xml · nonDerivative · entry 2 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 130,959 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in two transactions at prices $14.67 and $14.75. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 11:05 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 53,500 | $14.74 | $788,590.00 |
DisclosureSEC source: 0001209191-21-064378 · doc4.xml · nonDerivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,500 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in two transactions at prices $14.60 and $14.67. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 21:00 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | SaleCommon Shares | 1,200,000 | $25.50 | $30,600,000.00 |
DisclosureSEC source: 0000899243-21-022988 · doc4.xml · nonDerivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F1 · shares: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F1 · price: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionShare Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0000899243-21-022894 · doc4.xml · derivative · entry 5 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,950,000 Underlying: Common Shares · 600,000 shares Expires 2029-08-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 2,000,000 shares subject to the option vested and became exercisable on March 23, 2020. The remaining 3,550,000 shares (the "Remaining Shares") subject to the option vest and become exercisable as follows: 25% of the Remaining Shares subject to such option vested and became exercisable on August 22, 2020 and the remainder of the Remaining Shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionShare Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0000899243-21-022894 · doc4.xml · derivative · entry 4 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Shares · 600,000 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionCommon Shares | 600,000 | $0.32 | $192,000.00 |
DisclosureSEC source: 0000899243-21-022894 · doc4.xml · nonDerivative · entry 2 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionCommon Shares | 600,000 | $0.19 | $114,000.00 |
DisclosureSEC source: 0000899243-21-022894 · doc4.xml · nonDerivative · entry 1 Booth Andrew · CIK 0001834411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.